Lyme Disease

Pfizer invests $95m in Valneva

21-Jun-2022 By Rachel Arthur

Pfizer will invest €90.5m ($95m) in French vaccine specialist Valneva, representing 8.1% of Valneva’s share capital. The investment will support the duo’s Lyme disease vaccine partnership.

Valneva and Pfizer to take Lyme disease vaccine into Phase 3 trial this year

07-Feb-2022 By Rachel Arthur

Valneva and Pfizer have reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15, with a Phase 3 trial set to start in Q3, 2022.

Pfizer’s $308m buy-in for Lyme disease vaccine

04-May-2020 By Ben Hargreaves

Pfizer partners with Valneva to progress Phase II-stage vaccine candidate for Lyme disease.

GSK-Valneva end legacy vaccines partnership

25-Jun-2019 By Ben Hargreaves

GSK and Valneva have come to a mutual early termination agreement, as the former looks to ‘allocate capital to fewer, highest priority areas’.